— Updated Data Demonstrate Sustained Improvements in Hemoglobin to Normal Range at 6-months in First Patient and Similar 3-month Improvements in Second Patient Treated —
— Maintained Safety and Tolerability of RP-L301 up to 6-months Post-treatment —
— Long-Term Data on Track for 2H2021 —